

Eirik Bratland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6395911/publications.pdf>

Version: 2024-02-01

40
papers

987
citations

567281

15
h-index

454955

30
g-index

40
all docs

40
docs citations

40
times ranked

1284
citing authors

#	ARTICLE	IF	CITATIONS
1	Truncating and zinc-finger variants in <i>GLI2</i> are associated with hypopituitarism. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 1065-1074.	1.2	3
2	GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility. <i>Nature Communications</i> , 2021, 12, 959.	12.8	33
3	The natural history of 21-hydroxylase autoantibodies in autoimmune Addison's disease. <i>European Journal of Endocrinology</i> , 2021, 184, 607-615.	3.7	17
4	Biallelic <i>KARS1</i> pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease. <i>Human Mutation</i> , 2021, 42, 745-761.	2.5	7
5	Genome-Wide Association Study Links Autoimmune Addison's Disease to Break of Central Tolerance. <i>Journal of the Endocrine Society</i> , 2021, 5, A167-A168.	0.2	0
6	Gene Expression to Guide Glucocorticoid Replacement in Autoimmune Addison's Disease. <i>Journal of the Endocrine Society</i> , 2021, 5, A83-A83.	0.2	0
7	The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients. <i>Journal of Neuro-Oncology</i> , 2021, 154, 35-40.	2.9	4
8	Transcriptional Changes in Regulatory T Cells From Patients With Autoimmune Polyendocrine Syndrome Type 1 Suggest Functional Impairment of Lipid Metabolism and Gut Homing. <i>Frontiers in Immunology</i> , 2021, 12, 722860.	4.8	3
9	Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	18
10	Potential Transcriptional Biomarkers to Guide Glucocorticoid Replacement in Autoimmune Addison's Disease. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa202.	0.2	11
11	21-Hydroxylase-Specific CD8+ T Cells in Autoimmune Addison's Disease Are Restricted by HLA-A2 and HLA-C7 Molecules. <i>Frontiers in Immunology</i> , 2021, 12, 742848.	4.8	2
12	Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 342-359.	2.7	19
13	Coexistence of Congenital Adrenal Hyperplasia and Autoimmune Addison's Disease. <i>Frontiers in Endocrinology</i> , 2019, 10, 648.	3.5	2
14	Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease. <i>Journal of Translational Autoimmunity</i> , 2019, 1, 100005.	4.0	5
15	Autoimmune Addison's disease—An update on pathogenesis. <i>Annales D'Endocrinologie</i> , 2018, 79, 157-163.	1.4	47
16	Longitudinal cohort study of serum antibody responses towards <i>Giardia lamblia</i> variant-specific surface proteins in a non-endemic area. <i>Experimental Parasitology</i> , 2018, 191, 66-72.	1.2	21
17	The potential role for infections in the pathogenesis of autoimmune Addison's disease. <i>Clinical and Experimental Immunology</i> , 2018, 195, 52-63.	2.6	10
18	Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. <i>Oncolmmunology</i> , 2017, 6, e1336272.	4.6	17

#	ARTICLE	IF	CITATIONS
19	Altered Immune Activation and IL-23 Signaling in Response to <i>Candida albicans</i> in Autoimmune Polyendocrine Syndrome Type 1. <i>Frontiers in Immunology</i> , 2017, 8, 1074.	4.8	12
20	Anticommensal Responses Are Associated with Regulatory T Cell Defect in Autoimmune Polyendocrinopathyâ€“Candidiasisâ€“Ectodermal Dystrophy Patients. <i>Journal of Immunology</i> , 2016, 196, 2955-2964.	0.8	15
21	A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2975-2983.	3.6	112
22	Analysis of cellular and humoral immune responses against cytomegalovirus in patients with autoimmune Addisonâ€™s disease. <i>Journal of Translational Medicine</i> , 2016, 14, 68.	4.4	1
23	Hypomagnesemia and functional hypoparathyroidism due to novel mutations in the Mg-channel TRPM6. <i>Endocrine Connections</i> , 2015, 4, 215-222.	1.9	23
24	Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro, Despite Elevated Serum Levels of Interferon-Inducible Chemokines. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 759-770.	1.2	17
25	Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases. <i>Immunity</i> , 2015, 42, 1185-1196.	14.3	246
26	Interleukin-2 and subunit alpha of its soluble receptor in autoimmune Addison's disease â€“ An association study and expression analysis. <i>Autoimmunity</i> , 2015, 48, 100-107.	2.6	9
27	High Frequency of Cytolytic 21-Hydroxylaseâ€™Specific CD8+ T Cells in Autoimmune Addisonâ€™s Disease Patients. <i>Journal of Immunology</i> , 2014, 193, 2118-2126.	0.8	38
28	Functional studies of novel CYP21A2 mutations detected in Norwegian patients with congenital adrenal hyperplasia. <i>Endocrine Connections</i> , 2014, 3, 67-74.	1.9	10
29	CYP21A2 polymorphisms in patients with autoimmune Addison's disease, and linkage disequilibrium to HLA risk alleles. <i>European Journal of Endocrinology</i> , 2014, 171, 743-750.	3.7	9
30	The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease. <i>Clinical and Experimental Immunology</i> , 2014, 176, 351-362.	2.6	10
31	A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. <i>Clinical Immunology</i> , 2014, 153, 220-227.	3.2	16
32	Altered DNA methylation profile in Norwegian patients with Autoimmune Addison's Disease. <i>Molecular Immunology</i> , 2014, 59, 208-216.	2.2	21
33	Autoantibodies against aromatic amino acid hydroxylases in patients with autoimmune polyendocrine syndrome type 1 target multiple antigenic determinants and reveal regulatory regions crucial for enzymatic activity. <i>Immunobiology</i> , 2013, 218, 899-909.	1.9	9
34	Induction of CXCL10 chemokine in adrenocortical cells by stimulation through toll-like receptor 3. <i>Molecular and Cellular Endocrinology</i> , 2013, 365, 75-83.	3.2	18
35	Cellular immunity and immunopathology in autoimmune Addison's disease. <i>Molecular and Cellular Endocrinology</i> , 2011, 336, 180-190.	3.2	50
36	T Cell Responses to Steroid Cytochrome P450 21-Hydroxylase in Patients with Autoimmune Primary Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 5117-5124.	3.6	44

#	ARTICLE	IF	CITATIONS
37	The purification and application of biologically active recombinant steroid cytochrome P450 21-hydroxylase: The major autoantigen in autoimmune Addison's disease. <i>Journal of Autoimmunity</i> , 2009, 33, 58-67.	6.5	8
38	Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. <i>Clinical Immunology</i> , 2008, 129, 163-169.	3.2	75
39	Epitope mapping of human aromatic L-amino acid decarboxylase. <i>Biochemical and Biophysical Research Communications</i> , 2007, 353, 692-698.	2.1	1
40	The Substrate-Binding Domain of 21-Hydroxylase, the Main Autoantigen in Autoimmune Addison's Disease, Is an Immunodominant T Cell Epitope. <i>Endocrinology</i> , 2006, 147, 2411-2416.	2.8	24